J T Brozinick

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet
    J T Brozinick
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Int J Obes (Lond) 37:1064-70. 2013
  2. pmc "Actin"g on GLUT4: membrane & cytoskeletal components of insulin action
    Joseph T Brozinick
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Diabetes Rev 3:111-22. 2007
  3. pmc Disruption of cortical actin in skeletal muscle demonstrates an essential role of the cytoskeleton in glucose transporter 4 translocation in insulin-sensitive tissues
    Joseph T Brozinick
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 279:40699-706. 2004
  4. ncbi Defective signaling through Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance
    Joseph T Brozinick
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Diabetes 52:935-41. 2003
  5. pmc 1-[N, O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4- phenylpiperazine (KN-62), an inhibitor of calcium-dependent camodulin protein kinase II, inhibits both insulin- and hypoxia-stimulated glucose transport in skeletal muscle
    J T Brozinick
    Experimental Diabetes, Metabolism and Nutrition Section, DB NIDDK National Institutes of Health, Bethesda, MD 20892, USA
    Biochem J 339:533-40. 1999
  6. ncbi Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle
    J T Brozinick
    Howard Hughes Medical Institute, Department of Medicine and The Cox Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6148, USA
    J Biol Chem 273:14679-82. 1998
  7. ncbi GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure
    J T Brozinick
    Experimental Diabetes, Metabolism and Nutrition Section, DB NIDDK, National Institutes of Health, Bethesda, Maryland, USA
    Diabetes 50:593-600. 2001
  8. pmc Regulation of cell surface GLUT4 in skeletal muscle of transgenic mice
    J T Brozinick
    Experimental Diabetes, Metabolism and Nutrition Section, DB NIDDK National Institutes of Health, Bethesda, MD 20892, USA
    Biochem J 321:75-81. 1997
  9. pmc Transient enhancement of GLUT-4 levels in rat epitrochlearis muscle after exercise training
    T H Reynolds
    Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Appl Physiol (1985) 88:2240-5. 2000
  10. ncbi A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle
    J Mu
    Howard Hughes Medical Institute, The Cox Institute, The Department of Medicine, University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
    Mol Cell 7:1085-94. 2001

Collaborators

  • Anne Reifel Miller
  • T H Reynolds
  • JEFFREY ELMENDORF
  • M J Birnbaum
  • James R Henry
  • Isabel Rojo
  • J L Ivy
  • GERALD L DOHM
  • Jesper Gromada
  • Minmin Wang
  • Rosario Gonzalez
  • Kathleen M Ogilvie
  • G J Etgen
  • Ronit Rafaeloff Phail
  • Scott A Summers
  • Alexei Kharitonenkov
  • Radmila Micanovic
  • Alicia M McCarthy
  • Alan M Warshawsky
  • Anne Reifel-Miller
  • Emily M Horvath
  • William L Holland
  • Eric D Hawkins
  • Charles A Alt
  • Tony Y Zhang
  • Elizabeth A Misener
  • Chahrzad Montrose-Rafizadeh
  • Gary A Rhodes
  • Eric Hawkins
  • José A Martín
  • J Mu
  • Priya Raman
  • Lixuan Tackett
  • Li Ping Wang
  • Kyle L Hoehn
  • Trina A Knotts
  • Krishna Narra
  • Katherine M Sargent
  • Angela Siesky
  • Don H Nelson
  • Sotirios K Karathanasis
  • Greg K Fontenot
  • Yanqi Liu
  • Donald P Matthews
  • Richard W Zink
  • Uko E Udodong
  • Quanrong Shen
  • Jennifer A Vance
  • Kristen O Spisak
  • Anne R Miller
  • Allen R Harkness
  • Kay Klausing
  • Beatriz López de Uralde
  • Alan Warshawsky
  • Sharon Dana
  • Roger L Robey
  • Rafael Ferritto
  • Kelly Wilbur
  • Jose Alfredo Martin
  • Dawn A Brooks
  • María Dolores Martín-Ortega
  • Lourdes Prieto
  • Richard Zink
  • William R Bensch
  • Alicia Torrado
  • John R Rizzo
  • Robert Barr
  • Chahrzad Rafizadeh-Montrose
  • Chris Bull
  • James D Fraser
  • Roger Robey
  • Ronit Rafaeloff-Phail
  • Carlos Lamas
  • Francisco Parra
  • Daniel A Briere
  • Keith Otto
  • Deepa Rungta
  • David Snyder
  • Gary Rhodes
  • Samuel R Wendel
  • Tony Zhang
  • Robert Ardecky
  • Javier Agejas
  • M Bucan
  • O Valladares

Detail Information

Publications21

  1. pmc Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet
    J T Brozinick
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Int J Obes (Lond) 37:1064-70. 2013
    ..However, data are lacking in this regard from both humans and non-human primates...
  2. pmc "Actin"g on GLUT4: membrane & cytoskeletal components of insulin action
    Joseph T Brozinick
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Diabetes Rev 3:111-22. 2007
    ..The discussion will visit recent cell culture, whole animal, and human data highlighting membrane and cytoskeletal aspects of insulin resistance...
  3. pmc Disruption of cortical actin in skeletal muscle demonstrates an essential role of the cytoskeleton in glucose transporter 4 translocation in insulin-sensitive tissues
    Joseph T Brozinick
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 279:40699-706. 2004
    ..Furthermore, these findings support a distal actin-based role for N-WASP in insulin action in vivo...
  4. ncbi Defective signaling through Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance
    Joseph T Brozinick
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Diabetes 52:935-41. 2003
    ..Additionally, these data also show that different upstream or downstream signals may regulate the activity of the various Akt isoforms...
  5. pmc 1-[N, O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4- phenylpiperazine (KN-62), an inhibitor of calcium-dependent camodulin protein kinase II, inhibits both insulin- and hypoxia-stimulated glucose transport in skeletal muscle
    J T Brozinick
    Experimental Diabetes, Metabolism and Nutrition Section, DB NIDDK National Institutes of Health, Bethesda, MD 20892, USA
    Biochem J 339:533-40. 1999
    ..The results of the present study suggest that CAMKII might have a distinct role in insulin- and hypoxia-stimulated glucose transport, possibly in the vesicular trafficking of GLUT4...
  6. ncbi Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle
    J T Brozinick
    Howard Hughes Medical Institute, Department of Medicine and The Cox Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6148, USA
    J Biol Chem 273:14679-82. 1998
    ..These data provide further evidence that two distinct pathways exist for the stimulation of glucose transport in mammalian skeletal muscle...
  7. ncbi GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure
    J T Brozinick
    Experimental Diabetes, Metabolism and Nutrition Section, DB NIDDK, National Institutes of Health, Bethesda, Maryland, USA
    Diabetes 50:593-600. 2001
    ..In summary, despite an impairment in whole-body glucose tolerance, skeletal muscle of the old transgenic GLUT4 db/db mice is still insulin responsive in vitro and in vivo...
  8. pmc Regulation of cell surface GLUT4 in skeletal muscle of transgenic mice
    J T Brozinick
    Experimental Diabetes, Metabolism and Nutrition Section, DB NIDDK National Institutes of Health, Bethesda, MD 20892, USA
    Biochem J 321:75-81. 1997
    ....
  9. pmc Transient enhancement of GLUT-4 levels in rat epitrochlearis muscle after exercise training
    T H Reynolds
    Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Appl Physiol (1985) 88:2240-5. 2000
    ..We believe that the transient enhancement in GLUT-4 protein after exercise training is due to a short GLUT-4 half-life, a process that is primarily regulated by pretranslational mechanisms...
  10. ncbi A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle
    J Mu
    Howard Hughes Medical Institute, The Cox Institute, The Department of Medicine, University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
    Mol Cell 7:1085-94. 2001
    ..These data indicate that AMPK transmits a portion of the signal by which muscle contraction increases glucose uptake, but other AMPK-independent pathways also contribute to the response...
  11. pmc Loss of cortical actin filaments in insulin-resistant skeletal muscle cells impairs GLUT4 vesicle trafficking and glucose transport
    Alicia M McCarthy
    Dept of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Am J Physiol Cell Physiol 291:C860-8. 2006
    ..We propose that a component of insulin-induced insulin resistance in skeletal muscle involves defects in PIP(2)/F-actin structure essential for insulin-regulated glucose transport...
  12. pmc Glucose transport and GLUT4 protein distribution in skeletal muscle of GLUT4 transgenic mice
    J T Brozinick
    Experimental Diabetes, Metabolism, and Nutrition Section, DB NIDDK National Institutes of Health, Bethesda, MD 20892 1420, USA
    Biochem J 313:133-40. 1996
    ..Furthermore, GLUT4 overexpression is not coupled to glucose-metabolic capacity...
  13. pmc Antidiabetogenic effects of chromium mitigate hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance
    Emily M Horvath
    Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Center for Diabetes Research, Indianapolis, Indiana 46202, USA
    Mol Endocrinol 22:937-50. 2008
    ..These data predict a PM cholesterol basis for hyperinsulinemia-associated insulin resistance and importantly highlight the reversible nature of this abnormality...
  14. ncbi 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents
    José A Martín
    Lilly Research Laboratories, Division of Eli Lilly and Company, Lilly S A, Alcobendas 28108, Madrid, Spain
    Bioorg Med Chem Lett 15:51-5. 2005
    ..Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes...
  15. pmc FGF-21 as a novel metabolic regulator
    Alexei Kharitonenkov
    Lilly Research Laboratories, Division of Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Invest 115:1627-35. 2005
    ..Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes...
  16. ncbi Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents
    James R Henry
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 16:6293-7. 2006
    ..Novel tetrahydroisoquinolines have been developed as potent PPAR ligands. Evaluation of these compounds in PPARgamma responsive models of type 2 diabetes is described...
  17. ncbi Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands
    Alan M Warshawsky
    Eli Lilly and Co, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 16:6328-33. 2006
    ..Several compounds in this series have demonstrated potent plasma glucose and triglyceride lowering capability in rodent models of type 2 diabetes...
  18. ncbi A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models
    Garret J Etgen
    Division of Endocrine Research, Lilly Research Laboratories, Eli Lilly, Indianapolis, Indiana 46285, USA
    Diabetes 51:1083-7. 2002
    ....
  19. ncbi A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia
    Anne Reifel-Miller
    Endocrinology Division, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Mol Endocrinol 19:1593-605. 2005
    ..These findings show that PPARgamma full agonist activity is not necessary to achieve potent and efficacious insulin-sensitizing benefits and demonstrate the therapeutic advantages of a PPARalpha/gamma dual agonist...
  20. ncbi Measurement of contraction-stimulated GLUT-4 translocation in isolated skeletal muscle
    Joseph T Brozinick
    Endocrine Division, Eli Lilly and Co, Indianapolis, IN, USA
    Methods Mol Med 83:163-9. 2003
  21. ncbi Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance
    William L Holland
    Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA
    Cell Metab 5:167-79. 2007
    ..Second, they identify enzymes required for ceramide synthesis as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy...